The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts

Marta Broniarczyk-Czarniak; Agata Orzechowska; Piotr Gałecki

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

2/2020
vol. 36

Send email

Copy url:

Original paper

The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts

Marta Broniarczyk-Czarniak

¹

,

Agata Orzechowska

¹

,

Piotr Gałecki

¹

Department of Adult Psychiatry, Medical University of Lodz

Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 107–115

Online publish date: 2021/12/06

Article file

- 02R_IPiN_FARM_2020-2D.pdf [0.14 MB]

Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Broniarczyk-Czarniak M, Orzechowska A, Gałecki P. The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2020;36(2):107-115.

APA

Broniarczyk-Czarniak, M., Orzechowska, A.,  & Gałecki, P. (2020). The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 36(2), 107-115.

Chicago

Broniarczyk-Czarniak, Marta, Agata Orzechowska,  and Piotr Gałecki. 2020. "The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts". Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 36 (2): 107-115.

Harvard

Broniarczyk-Czarniak, M., Orzechowska, A.,  and Gałecki, P. (2020). The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 36(2), pp.107-115.

MLA

Broniarczyk-Czarniak, Marta et al. "The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts." Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, vol. 36, no. 2, 2020, pp. 107-115.

Vancouver

Broniarczyk-Czarniak M, Orzechowska A, Gałecki P. The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2020;36(2):107-115.

1. Auquier, P., Lancon, C., Rouillon, F., Lader, M. and Holmes, C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006; 15(12): 873-9.

2. Charlson, F.J., Ferrari, A.J., Santomauro, D.F., Diminic, S., Stockings, E., Scott et al., Global Epidemiology and Bur den of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin 2018; 44(6): 1195-1203.

3. Chesney, E., Goodwin, G.M. and Fazel, S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13(2): 153-160.

4. Crump, C., Winkleby, M.A., Sundquist, K. and Sundquist, J. Comorbidities and Mortality in Persons With Schizophre nia: A Swedish National Cohort Study. American Journal of Psychiatry 2013; 170(3): 324-333.

5. Galderisi, S., Bucci, P., Ucok, A. and Peuskens, J. No gender differences in social outcome in patients suffering from schizophrenia. European Psychiatry 2012; 27(6): 406-408.

6. Gogos, A., Ney, L.J., Seymour, N., Van Rheenen, T.E. and Fel mingham, K.L. Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link? British Journal of Pharmacology 2019; 176(21): 4119-4135.

7. Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., Veijola, J. and Miettunen, J. A Systematic Review and Meta-Analysis of Recovery in Schizophrenia. Schizophrenia Bulletin 2013; 39(6): 1296-1306.

8. Kahn, R.S., Sommer, I.E., Murray, R.M., Meyer-Lindenberg, A., Weinberger, D.R., Cannon i wsp., Schizophrenia. Nature Reviews Disease Primers 2015; 1.

9. Kay, S.R., Fiszbein, A. and Opler, L.A. The positive and ne gative syndrome scale (PANSS) for schizophrenia. Schizo phrenia Bulletin 1987; 13(2): 261-276.

10. Kirschner, M., Aleman, A. and Kaiser, S. Secondary nega tive symptoms - A review of mechanisms, assessment and treatment. Schizophr Res 2017; 186: 29-38.

11. Koster, A., Lindhardt, A., Lajer, M. and Rosenbaum, B. Gen der differences in first episode psychosis. Social Psychiatry and Psychiatric Epidemiology 2008; 43(12): 940-946.

12. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li. i wsp., Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.

13. Lora, A., Kohn, R., Levav, I., McBain, R., Morris, J. and Sa xena, S. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bulletin of the World Health Or ganization 2012; 90(1): 47-54.

14. McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C. and Chant, D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology 2004; Bmc Medicine, 2.

15. Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A. et al., Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (In terSePT). Archives of General Psychiatry 2003; 60(1): 82-91.

16. Ochoa, S., Usall, J., Cobo, J., Labad, X. and Kulkarni, J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012; 916198.

17. Piotrowski, P., Gondek, T.M., Krolicka-Deregowska, A., Mi siak, B., Adamowski, T. and Kiejna, A. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatria Danubina 2017; 29(2): 108-120.

18. Pompili, M., Amador, X.F., Girardi, P., Harkavy-Friedman, J., Harrow, M., Kaplan, K. et al., Suicide risk in schizophre nia: learning from the past to change the future. Ann Gen Psychiatry 2007; 6-10.

19. Saha, S., Chant, D. and McGrath, J. A systematic review of mor tality in schizophrenia: is the differential mortality gap wor sening over time? Arch Gen Psychiatry 2007; 64(10): 1123-31.

20. Saha, S., Chant, D., Welham, J. and McGrath, J. A systematic review of the prevalence of schizophrenia. Plos Medicine 2005; 2(5): 413-433.

21. Simms, J., McCormack, V., Anderson, R. and Mulholland, C. Correlates of self-harm behaviour in acutely ill patients with schizophrenia. Psychology and Psychotherapy-Theory Research and Practice 2007; 80: 39-49.

22. Sun, J., Walker, A.J., Dean, B., van den Buuse, M. and Gogos, A. Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. Psychoneu roendocrinology 2016; 74: 126-140.

23. Szulc, A., Dudek, D., Samochowiec, J., Wojnar, M., Heitzman, J. and Gałecki, P. Recommendations for the treatment of schizophrenia with negative symptoms. Standards of phar macotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 2. Psychiatr Pol 2019; 53(3): 525-540.

24. Szymanski, S., Lieberman, J.A., Alvir, J.M., Mayerhoff, D., Loebel, A., Geisler, S. i wsp., Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry 1995; 152(5): 698-703.

25. Zhang, X.Y., Chen, D.C., Xiu, M.H., Yang, F.D., Haile, C.N., Kosten, T.A. i wsp., Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizo phrenia Patients. Journal of Clinical Psychiatry 2012; 73(7): 1025-1033

The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts

Marta Broniarczyk-Czarniak 1 , Agata Orzechowska 1 , Piotr Gałecki 1

Marta Broniarczyk-Czarniak

¹

,

Agata Orzechowska

¹

,

Piotr Gałecki

¹